Home › Ureteral Cancer
Ureteral Cancer clinical trials recruiting in the U.S.
8 studies for Ureteral Cancer are recruiting participants at sites across the United States.
Cities with the most studies
By state
- California3 studies
- Colorado3 studies
- Florida3 studies
- Georgia3 studies
- Illinois3 studies
- Indiana3 studies
- Massachusetts3 studies
- Michigan3 studies
- Minnesota4 studies
- Missouri3 studies
- New York3 studies
- North Carolina3 studies
- Ohio4 studies
- Texas3 studies
- Utah3 studies
Recently updated studies
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT06465069Enfortumab Vedotin and Pembrolizumab With Cystectomy and/or Ureterectomy for Locally Advanced or Metastatic Bladder and Upper Urothelial Tract Cancer, CAST-AI Trial
RecruitingPhase 4
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT06764095Enfortumab Vedotin, Pembrolizumab and Quemliclustat for the Treatment of Unresectable Locally Advanced and Metastatic Urothelial Cancer
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT07667335ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
RecruitingObservational study
Ages 18 and older · All sexes · Updated Sep 14, 2026 · NCT05059444FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 20, 2026 · NCT05614739Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jul 29, 2026 · NCT05756569Integrated Cancer Repository for Cancer Research
RecruitingObservational studyHealthy volunteers welcome
Ages 19 to 110 · All sexes · Updated Jun 29, 2026 · NCT02012699Therapeutic Plasma Exchange With Enfortumab Vedotin and Pembrolizumab for Treatment of Bladder Cancers
RecruitingPhase 2
Ages 18 and older · All sexes · Updated May 8, 2026 · NCT07087860From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.